Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT02595034 Completed - Acne Vulgaris Clinical Trials

A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris

Start date: January 2015
Phase: Phase 1
Study type: Interventional

This study is to evaluate the therapeutic equivalence and safety of Clindamycin and Benzoyl Peroxide Gel 1%/5% and BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel

NCT ID: NCT02593383 Completed - Acne Clinical Trials

Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne

Start date: March 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

evaluate the safety and efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in treatment of chinese patients with acne.

NCT ID: NCT02589405 Completed - Acne Vulgaris Clinical Trials

Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

Benzac
Start date: August 2015
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate a complete acne regimen consisting of a medication (Benzaknen® 5% Gel), and 2 cosmetic products Dermotivin® Soft Liquid soap and Cetaphil® Dermacontrol Moisturizer SPF30 in patients with acne.

NCT ID: NCT02581072 Completed - Acne Vulgaris Clinical Trials

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Start date: October 2015
Phase: Phase 1
Study type: Interventional

A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study

NCT ID: NCT02578043 Completed - Acne Vulgaris Clinical Trials

A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris

Start date: April 2015
Phase: Phase 1
Study type: Interventional

The objectives of this study are to evaluate the therapeutic equivalence and safety.

NCT ID: NCT02575950 Completed - Acne Vulgaris Clinical Trials

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Start date: June 2016
Phase: Phase 2
Study type: Interventional

An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.

NCT ID: NCT02571998 Completed - Acne Vulgaris Clinical Trials

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Start date: October 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory acne vulgaris.

NCT ID: NCT02566369 Completed - Acne Vulgaris Clinical Trials

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

NCT ID: NCT02557399 Completed - Acne Vulgaris Clinical Trials

DUAC® Early Onset Efficacy Study in Japanese Subjects

Start date: October 7, 2015
Phase: Phase 4
Study type: Interventional

This is a multicentre, randomized, single-blind (investigator is blinded), active (the combination therapy of adapalene [ADA] and clindamycin [CLDM])-controlled and parallel-group study in Japanese subjects with facial acne vulgaris. The purpose of this study is to evaluate the efficacy, safety and tolerability of CLDM 1 percent (%)-benzoyl peroxide 3% (Duac®: trademark owned by GlaxoSmithKline) once daily fixed dose combination gel versus combination therapy of ADA 0.1% gel and CLDM 1% gel in the topical treatment of facial acne vulgaris for 12 weeks. A total of 400 subjects will be screened for enrolment. Subjects will use Duac® fixed dose combination gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) or combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks.

NCT ID: NCT02556788 Completed - Acne Vulgaris Clinical Trials

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

Start date: November 2015
Phase: Phase 3
Study type: Interventional

Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.